Vaxart files preliminary proxy; urges support for board nominees amid dissident challenge

Vaxart, Inc.

Annual meeting set for July 16, 2026; preliminary proxy filed with SEC.
Dissident shareholder group nominated three candidates; company says they lack relevant biotech experience.
Cash resources ~$61M as of Q1 2026; funded runway into Q2 2027.
BARDA COVID-19 Phase 2b trial restored after stop-work order; main cohort primary readout expected early 2027.
CEO holds over 2.5M shares and has never sold a share; board added Dr. James Breitmeyer in 2025.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.